Wanbury News: Dextromethorphan Certificate of Suitability for Cough Relief
Maharashtra: Wanbury Limited has announced that it has been awarded a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines (EDQM) for its dextromethorphan-based cough relief medicine. This certification underscores the company’s commitment to excellence in pharmaceutical innovation and enables greater accessibility to effective cough treatments within the European market.
The Importance of Dextromethorphan
Dextromethorphan is widely recognized for its effectiveness in treating coughs. Its safety and efficacy make it a preferred choice among healthcare providers.
Regulatory Compliance and Market Impact
The Certificate of Suitability signifies that Wanbury's product meets the stringent quality requirements set forth by European authorities.
- Enhanced product trust among healthcare professionals.
- Increased market competitiveness within the healthcare industry.
- Boost in patient access to essential medications.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.